| ²é¿´: 773 | »Ø¸´: 4 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
xiaomao225гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
µÚÒ»¾äÔõô·Òë ÒÑÓÐ2È˲ÎÓë
|
|
|
Õâ¾ä»°Ôõô·Ò룿ֻ·ÒëÕâ¾ä¼´¿É¡£TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. ²»Ó÷ÒëAbstract¡£ Abstract The aim of this study was to investigate the inhibitory effect of TSU68 [(Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid; SU6668], an inhibitor of vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor beta, and fibroblast growth factor receptor 1 (FGFR1), on colon cancer liver metastasis, and to test the hypothesis that TSU68 modulates the microenvironment in the liver before the formation of metastasis. First, we implanted the highly metastatic human colon cancer TK-4 orthotopically into the cecal walls of nude mice, followed by twice-daily administration of TSU68 (400 mg/kg/d) or vehicle. Five weeks of treatment with TSU68 significantly inhibited liver metastasis compared with the control group (P<0.001). Next, we analyzed the gene expression profile in premetastatic liver using microarrays. Microarray and quantitative reverse transcription-PCR analysis showed that mRNA levels for the chemokine CXCL1 were significantly increased in tumor-bearing mice compared with non-tumor-bearing mice. Moreover, CXCL1 expression was significantly decreased by TSU68 treatment. CXCR2 expression was detected predominantly on tumor cells in orthotopic tumors compared with ectopic tumors. The number of migrating neutrophils in premetastatic liver was significantly decreased in the TSU68-treated group (P<0.001). The amount of interleukin-12 (IL-12) p40 in the portal vein was significantly decreased by TSU68 (P=0.02). Blockade of both CXCR2 and IL-12 p40 with a neutralizing antibody significantly inhibited liver metastasis. These results suggest that the CXCL1/CXCR2 axis is important in cancer metastasis and that TSU68 may modulate the premetastatic niche in the target organ through suppression of the inflammatory response, which might be an alternative mechanism used by antiangiogenic agents. |
» ²ÂÄãϲ»¶
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ16È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
processesÔõô·Òë
ÒѾÓÐ7È˻ظ´
Õâ¸öÔõô·Òë°¡£¿
ÒѾÓÐ4È˻ظ´
ÇóÖúÕâ¾ä»°ÔõÑù·Ò룬Á½¸öbyÊÇÔõô·Ò룿
ÒѾÓÐ2È˻ظ´
Çë½Ì¡°ÒýÖ¤ÎÄÏס±Ôõô·Ò룿
ÒѾÓÐ10È˻ظ´
ÇëÎÊ´¨´óÓ¢Ó︴ÊÔÏß»®¶¨µÄ±ÈÀýÊÇÔõÑùµÄ£¿
ÒѾÓÐ15È˻ظ´
Ó¢ÎÄÎÄÏ×Ôõô·Ò룿
ÒѾÓÐ10È˻ظ´
¾³£Óöµ½Ò»Ð©Ó¢Îĵ¥´ÊÓеÀÖ®Àà¶¼ÎÞ·¨·Ò룬ÔõÃ´ÆÆ
ÒѾÓÐ19È˻ظ´
Çë½ÌÕâ¾ä»°Ó¦¸ÃÔõô·Ò룬лл£¡
ÒѾÓÐ4È˻ظ´
Ò»¶ÎÓ¢ÎÄ·Òë³ÉÖÐÎÄ Ôõô¶Ï¾ä
ÒѾÓÐ2È˻ظ´
ASME Fellow Ôõô·Òë
ÒѾÓÐ9È˻ظ´
Highlights×Ö·ûÊý³¬ÁËЩ£¬Ôõô°ì£¿
ÒѾÓÐ27È˻ظ´
ÌØ¼¶ Ò»¼¶ ¶þ¼¶ Ôõô·ÒëÄØ
ÒѾÓÐ9È˻ظ´
0.2 mM in 10 mLÔõô·Ò룬ÓÈÆäÊÇmMÊÇʲôÒâ˼ ?
ÒѾÓÐ11È˻ظ´
¸ø¹úÍâ½ÌÊÚдÓʼþµÄµÚÒ»¾ä»°Ó¦¸ÃÔõôд£¿
ÒѾÓÐ6È˻ظ´
ÔÚÒ©ÎﻯѧÖÐ PK profile Ôõô·Òë ÊÇʲôÒâ˼°¡
ÒѾÓÐ11È˻ظ´
ÖÐÎÄÖеĶ̾äÔÚÓ¢ÎÄÖиÃÔõô·Ò룿
ÒѾÓÐ8È˻ظ´
ͶӢÎÄÎÄÕÂÔõô·ÒëµÄ£¿
ÒѾÓÐ16È˻ظ´
lzlqy2010
гæ (СÓÐÃûÆø)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 148.4
- ºì»¨: 17
- Ìû×Ó: 196
- ÔÚÏß: 146.8Сʱ
- ³æºÅ: 3111430
- ×¢²á: 2014-04-03
4Â¥2015-05-13 12:10:53
lzlqy2010
гæ (СÓÐÃûÆø)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 148.4
- ºì»¨: 17
- Ìû×Ó: 196
- ÔÚÏß: 146.8Сʱ
- ³æºÅ: 3111430
- ×¢²á: 2014-04-03
2Â¥2015-05-12 10:57:08
xiaomao225
гæ (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 1716.1
- É¢½ð: 171
- ºì»¨: 9
- Ìû×Ó: 609
- ÔÚÏß: 158.2Сʱ
- ³æºÅ: 3015889
- ×¢²á: 2014-03-04
- רҵ: ΢ÉúÎïѧ
3Â¥2015-05-13 00:36:07
818james
ͳæ (ÖøÃûдÊÖ)
- Ó¦Öú: 59 (³õÖÐÉú)
- ½ð±Ò: 7611.1
- ºì»¨: 17
- Ìû×Ó: 1455
- ÔÚÏß: 878.1Сʱ
- ³æºÅ: 3719023
- ×¢²á: 2015-03-08
5Â¥2015-05-16 00:14:02













»Ø¸´´ËÂ¥
